Welcome Daniela Sica, Vice President, Business Development, Pharma and Biotech

News
Category:
Published on:
December 15, 2020

BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is pleased to announce that Daniela Sica has joined the firm as Vice President, Business Development, Pharma and Biotech. Daniela has extensive experience in the pharmaceutical and biotech space, and is based out of Alira Health’s Barcelona, Spain office.

We are thrilled to welcome Daniela to the Alira Health Team,” said Benjamin Chambon, Chief Commercial Officer and EVP, Transaction Advisory. “Her notable experience in the pharma and biotech field will play a critical role in further enhancing the Alira Health lifecycle offering, and, in turn, continuing to improve synergies across our practice areas for the benefit of our clients.”
I have been following the evolution of Alira Health for several years, prior to joining the team,” said Daniela. “I have always admired the passion and commitment of the founders and leadership team, and the depth of expertise within the company. I am thrilled to join Alira Health at this exciting stage of its development.”

Daniela has over 25 years of management experience with pharmaceutical and biotech companies, and CDMOs. She has worked in business development, alliance management, and strategic planning with worldwide responsibilities, building a strong network of international relationships. Daniela has strong transaction experience, having led negotiations in co-development deals involving some of the largest global pharma companies.

Daniela sits on several biotech evaluation commissions, supporting biotech accelerators in their investment decisions. She has a degree in Food Science and Technology from the University of Milan, with a qualification as a Food Science Expert.

Learn more about our Team

Click here

Related news

MedTech Pharma
Publications February 8, 2021
Infographic: 2021 Trends in Healthcare
It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.
MedTech Pharma
News February 4, 2021
2020 Year in Review
With 2021 in full swing, we want to take a moment to reflect on last year’s achievements and congratulate the entire Alira Health Team for their hard work and dedication to healthcare(...)
M&A Pharma
News December 20, 2020
We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS
We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.
Market Access Pharma
Publications November 2, 2020
WHO Guideline: Summary of Recommendations on Pharmaceutical Pricing Policies
The WHO recently launched a series of recommendations on pharmaceutical pricing policies to help countries make medicines more affordable for the global population and lessen the burden(...)
Advanced Analytics Market Access Pharma
Publications November 1, 2020
Our Parallel Trade Expertise
Alira Health is proud to announce our new collaboration with Mark Inigo Jones, an industry leader in European parallel trade of pharmaceutical products.
Pharma
Publications August 1, 2020
Pre-Commercial Value Assessment of a Nuclear Medicine Pair to Diagnose and Treat Neuroendocrine Tumors (NET)
When our client, a leading radiopharmaceutical company, needed support to understand the commercial opportunity represented by a Phase III radiopharmaceutical and its diagnostic radiotracer(...)
Pharma Regulatory
News July 9, 2020
We Welcome Olga Carroll, PhD as Vice President, Global Regulatory Affairs
We are pleased to announce that Olga Carroll, Ph.D. joined the firm as Vice President of Regulatory.

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.